OBOxana Bujor

Oxana Bujor

*This is an algorithmically generated author record based on publicly available information.

Oxana Bujor has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Calprotectin – clinical and diagnostic value in rheumatoid arthritis

    by Vlada Zanosiev, Eugen Russu, Oxana Bujor, Liliana Groppa

    Introduction. Rheumatoid arthritis is a systemic autoimmune disease in which persistent synovitis drives joint destruction and disability. Conventional biomarkers such as C-reactive protein and erythrocyte sedimentation rate are widely used to assess disease activity, but they fail to capture inflammation in a considerable proportion of patients and may be confounded by therapies such as interleukin-6 inhibition. Calprotectin (S100A8/A9, MRP8/14), a neutrophil- and monocytederived alarmin, has emerged as a potential biomarker reflecting the true inflammatory burden in rheumatoid arthritis. This review aimed to critically appraise the clinical and diagnostic value of calprotectin in adult rheumatoid arthritis, with emphasis on its relationship to disease activity, comparative performance against C-reactive protein and erythrocyte sedimentation rate, methodological aspects of measurement, and role in therapeutic monitoring. Material and methods. We systematically reviewed studies published between 2010 and 2025 that investigated calprotectin in adult rheumatoid arthritis, focusing on serum, plasma, synovial fluid, and fecal measurements, and their associations with disease activity, imaging, treatment response, and outcomes. Additionally, seminal articles published before 2010 were included when they provided essential historical context or foundational theoretical data relevant to the understanding of calprotectin in rheumatoid arthritis. Pediatric and animal studies were excluded. Results. Serum calprotectin is consistently elevated in rheumatoid arthritis compared with healthy controls and correlates strongly with swollen joint counts, composite indices, and ultrasound-detected synovitis, often outperforming C-reactive protein and erythrocyte sedimentation rate. Synovial fluid calprotectin is markedly increased, reflecting local production and aggressive synovitis, while fecal calprotectin has limited utility except in cases of concomitant gastrointestinal involvement. Importantly, calprotectin levels remain reliable in patients receiving IL-6 inhibitors, where C-reactive protein is suppressed. High baseline calprotectin predicts radiographic progression and poor functional outcomes, whereas declining levels parallel therapeutic response to DMARDs and biologics. Recent studies suggest calprotectin may help identify patients at risk of relapse during apparent remission, though its predictive value for treatment response to TNF inhibitors appears limited. Conclusions. Calprotectin is a sensitive biomarker of inflammation in rheumatoid arthritis, offering distinct advantages over traditional acute-phase reactants in detecting residual disease and guiding therapeutic monitoring. Standardisation of assays, establishment of validated cut-off values, and large prospective validation studies are required before routine integration into clinical practice.

  • Open Access

    Evaluarea dismicrobismului intestinal la pacienții cu sclerodermie sistemică: dezechilibre între flora patogenă și bacteriile comensale

    by Maria Lungu, Svetlana Agachi, Liliana Groppa, Oxana Bujor, Rodica Usatîi, Lilia Taran

    Systemic scleroderma (SS) is a rare autoimmune disease characterized by cutaneous and visceral fibrosis, vascular and immunological involvement. In recent years, the intestinal dysmicrobism has been recognized as an important factor in regulating the immune response and in the development of chronic inflammation. Intestinal dysmicrobism defined as the imbalance between commensal and pathogenic bacteria, has been associated with the severity and activity of the disease in SS. To evaluate the intestinal microbiota profile in patients with systemic scleroderma and to analyze the relationship between the microbiota imbalance and gastrointestinal clinical manifestations. The study included 74 patients with SS (70 women, 4 men, mean age 57.74 ± 1.05 years), hospitalized in 2024-2025 in rheumatology departments in the Republic of Moldova. The limited form was present in 64.86%, and the diffuse form in 35.14%. The status of the intestinal microbiota was assessed bacteriologically from intestinal content samples. Patients with SS showed a significant reduction in commensal bacteria (especially Lactobacillus species, Bifidobacterium spp.) and an increase in opportunistic and pro-inflammatory species (Escherichia coli, Candida spp., Klebsilla pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Citrobacter freundi, Enterobacter cloacae). Dysmicrobism was identified in 85.14% of patients and correlated with the severity of digestive symptoms, especially dysphagia and heartburn. Intestinal dysmicrobism is common (85.14%) in SS and reflects an imbalance between protective and pathogenic flora. These changes may contribute to systemic inflammation and digestive dysfunction, highlighting the importance of evaluating the microbiota as a diagnostic and therapeutic tool.